Stephens Reiterates Overweight Rating for CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA)‘s stock had its “overweight” rating restated by Stephens in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $15.00 price target on the stock. Stephens’ price objective points to a potential upside of 82.26% from the company’s previous close.

CareDx Trading Up 4.8 %

CDNA stock traded up $0.38 during trading on Wednesday, reaching $8.23. 865,424 shares of the stock were exchanged, compared to its average volume of 903,682. The firm’s 50 day moving average is $9.72 and its 200 day moving average is $9.16. The firm has a market cap of $426.15 million, a P/E ratio of -2.34 and a beta of 1.42. CareDx has a twelve month low of $4.80 and a twelve month high of $12.93.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($1.97). CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The company had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. During the same quarter last year, the company posted ($0.34) EPS. The company’s quarterly revenue was down 20.4% compared to the same quarter last year. As a group, analysts predict that CareDx will post -1.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CareDx

Institutional investors and hedge funds have recently bought and sold shares of the company. Citigroup Inc. lifted its position in shares of CareDx by 7.1% during the third quarter. Citigroup Inc. now owns 132,560 shares of the company’s stock worth $928,000 after acquiring an additional 8,768 shares in the last quarter. ARK Investment Management LLC grew its position in shares of CareDx by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 7,194,722 shares of the company’s stock valued at $86,337,000 after purchasing an additional 515,399 shares in the last quarter. First Eagle Investment Management LLC raised its position in shares of CareDx by 38.7% in the third quarter. First Eagle Investment Management LLC now owns 1,005,189 shares of the company’s stock worth $7,036,000 after buying an additional 280,345 shares in the last quarter. Swiss National Bank raised its holdings in shares of CareDx by 2.3% in the 3rd quarter. Swiss National Bank now owns 118,200 shares of the company’s stock valued at $827,000 after acquiring an additional 2,700 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of CareDx by 1.2% during the third quarter. Vanguard Group Inc. now owns 4,138,591 shares of the company’s stock worth $28,970,000 after purchasing an additional 50,667 shares in the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.